Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2021.01.13
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment ...
2020.12.14
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metas ...
PDF (205 KB)
2020.12.14
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docet ...
PDF (224 KB)
2020.12.10
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Pos ...
PDF (304 KB)
2020.12.10
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with H ...
PDF (296 KB)
2020.11.17
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
PDF (268 KB)
2020.11.12
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organ ...
PDF (181 KB)
2020.11.02
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER ...
PDF (302 KB)
2020.10.28
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Canc ...
PDF (296 KB)
2020.10.22
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activ ...
PDF (125 KB)
Showing 1 - 10 of 36 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...